- Home
- SONO vs GLUE Comparison
SONO vs GLUE Comparison
Compare SONO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SONO | GLUE |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SONO | GLUE |
|---|---|---|
| Price | $13.62 | $24.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $19.67 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.5M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,443,276,000.00 | $123,672,000.00 |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $6.53 | $2.45 |
| P/E Ratio | ★ $26.19 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $10.12 | $4.12 |
| 52 Week High | $19.82 | $25.77 |
Technical Indicators
Market Signals| Indicator | SONO | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 77.08 |
| Support Level | $12.67 | $17.35 |
| Resistance Level | $15.69 | $25.56 |
| Average True Range (ATR) | 0.64 | 1.52 |
| MACD | -0.13 | 0.65 |
| Stochastic Oscillator | 21.51 | 87.44 |
Price Performance
Historical ComparisonAbout SONO Sonos Inc.
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).